QCIG
SRPT icon

Quad-Cities Investment Group’s Sarepta Therapeutics SRPT Stock Holding History

Quad-Cities Investment Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400
Closed -$30K – 633
2019
Q3 		$30K Buy
400
+200
+100% +$23.6K 0.03% 415
2019
Q2 		$30K Sell
200
-200
-50% -$24.3K 0.03% 424
2019
Q1 		$48K Buy
400
+200
+100% +$25.7K 0.04% 342
2018
Q4 		$22K Hold
200
– – 0.02% 466
2018
Q3 		$32K Hold
200
– – 0.03% 432
2018
Q2 		$26K Buy
+200
New +$18.9K 0.02% 477

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Quad-Cities Investment Group's SRPT Position: Q4 2019 in Review

Quad-Cities Investment Group sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 400 shares — an estimated $30K sold.

Quad-Cities Investment Group first reported a position in SRPT in Q2 2018 and held it in 6 quarters. The position peaked at $48K in Q1 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Quad-Cities Investment Group reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Quad-Cities Investment Group sold 400 Sarepta Therapeutics shares in Q4 2019, an estimated $30K.
  • Quad-Cities Investment Group first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 6 quarters.
  • Quad-Cities Investment Group's Sarepta Therapeutics position peaked at $48K in Q1 2019.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Quad-Cities Investment Group's 13F filing for Q4 2019, filed 28 Jan 2020.